

FIG. 1.

Multiple Alignment:

| | | | |
|------------------------|------------|---|------------|
| 30664188.0.99 VEGFE | 1 | MHR LI FVYT LICANFC SCR DT SATPQSAS I KALRNAMFLRDES N HLT DLY R RDE TI Q WKG 1 - - M S L E G L L I L T S A L A G Q E Q GT Q A E S N L S S K F Q F S S N K - - E Q N G V Q D P Q - H E R I I T V S T | 60 54 |
| 30664188.0.99 VEGFE | 61 55 | NG Y V Q S P R E P N S Y P R E N L L I T W R L H S - Q E N T R I Q L Y F D N Q F G L E A E N D I C R Y D F V E V E D I NG S I H S P R E P H T Y P R E N T V L W W R L V A T E E N W W I Q L T F D E R F G L E D P E D D I C K Y D F V E V E E P | 119 114 |
| 30664188.0.99 VEGFE | 120 115 | S E T S T I I R G R W C G H K E W P P R I K S R T N Q K I T F K S D D I F V A K P G E K I Y W S L L E D F Q P A A S S D G - - T I I G R W C G S G T W P G K Q I S K G N Q I R I R F V S D E E V F P S E P G F C I H W N I V M P - - - - - - - - - - 165 | 179 |
| 30664188.0.99 VEGFE | 180 166 | E T N W E S V T S S I S G W S Y N S P S V T D P - T L I A D A D L D K K I A E F D T V E D L K Y F N P E S W Q E D L I E N - - - - - Q F T E A V S - - - - - P S V L P P S A L P L D I L N N A I T A F S T L E D L I R Y L E P E R W Q L D L I E D | 238 214 |
| 30664188.0.99 VEGFE | 239 215 | M Y L D T P R Y R E R S Y H D - R K S - K W D L D R I N D D A K R Y S C T P R N Y S W N I R E E L K L A N V V F F P R G L Y R P T W Q L I E K A F V F G R K S R V W D I N L I T E E V R L Y S C T P R N E S W S I R E E L K R T D T I E W P G S | 296 274 |
| 30664188.0.99 VEGFE | 297 275 | L L V Q R C G G N C G C G T V M W R S S T T N S G K T V K K Y H E V L Q F E P G H I K R R G R A K T M A L V D I Q L D H L L V K R C G G N C A C C L H N C N E Q S W P S K V T K K Y H E V L Q L R P - - - K T G V R G L H K S I T D V A L E H | 356 331 |
| 30664188.0.99 VEGFE | 357 332 | H E R C D C I C S S R P P R (SEQ ID NO:2) H E E C D C V R G S T G G (SEQ ID NO:28) | 370 345 |

FIG. 2.



FIG. 3.

FIG. 4A

IgK 30664188 V5 His
aa 24-370




FIG. 4B

FIG. 5.




FIG. 6.

BrdU Proliferation NIH 3T3 5-24





FIG. 7.






FIG. 9.

Growth 5-15-00 NHost




FIG. 10.

FIG. 10A (without serum)




FIG. 10B (with serum)




FIG. 11.




FIG. 12

*

| | |
|---------|--|
| hPDGF D | CTPRNYSVNI - REELKLANVVF - - FPRCLLVQRCGGNCACCGTVNWRSCTC |
| mPDGF D | CTPRNHSVNL - REELKLTNAVF - - FPRCLLVQRCGGNCACCGTVNWKSCTC |
| PDGF C | CTPRNFSVSI - REELKRTDTIF - - WPGCLLVKRCGGNCACCLHNCNECQC |
| PDGF B | CKTRTEVFEISRRLIDRTNANFLVWPPCVEQRCSG - - - CNNRNVQCRP |
| PDGF A | CKTRTVIYEIPRSQVDPTSANFLIWPPCVEVKRCTG - - - CCNTSSVKCQP |
| hPDGF D | NS - - GKTVKKYHEVLQFEPGHIKRRGRAKTMALVDIQLDHHERCDC (SEQ ID NO:15) |
| mPDGF D | SS - - GKTVKKYHEVLKFEPGHFKRRGAKNMALVDIQLDHHERCDC (SEQ ID NO:16) |
| PDGF C | VP - - SKVTKKYHEVLQLRPKTGVRLH - KSLTDVA - - LEHHEECDC (SEQ ID NO:17) |
| PDGF B | TQVQLRPVQVRKIEIVRKPIF - - - KKAT - VT - - LEDHLACKC (SEQ ID NO:18) |
| PDGF A | SRVHHRSVKVAKVEYVRKKPKL - - - KEVQ - VR - - LEEHLECAC (SEQ ID NO:19) |

FIG. 13

Exon 1
1 DGCAGGGGGGGCGGGGTGCGTGGGAGCAGAACCCGGCTTTTCTTGGAGGACGGCTGTCTAGTGCTGATCCCA
81 AATG[]ACCGGCTCATTTGCTACACTCTAATCTGCCAAACTTTGCAAGCTGCGGACACTTCTGCAACCCGGAGA
M H R L I F V Y T L I C A N F C S C R D T S A T P Q S
161 GCGCATCCATCAAAGCTTGGCGAACGGCAACCTCAGGGAGATGAGGAAATCACCTCACAGACTTGTAACCGAAGAGAT
A S I K A L R N A N L R R D E S N H L T D L Y R R D
241 GAGACCACAGGTGAAAGGAAACGGCTACGTGCAAGAGTCAGATTGGAAACAGCTACCCAGGAACCTGCTCTGAC
E T I Q V K G N G Y V Q S P R F P N S Y P R N L L L T
321 ATGGGGGTTCACTCTCAGGAGAACACGGATAACAGCTAGTGTGTTGACAATCAGTTGGATTAGAGGAAGCAGAAAATG
U R L H S Q E N T P I Q L V F D N Q F G L E E A E N D
401 ATATCTGTAAGTATGATTTGGAAAGTTGAAGATATATCGAAACCGTAGGATTATTAGAGGGACGATGTTGACAC
I C R Y D F V E V E D I S E T S T I I R G R W C G H
481 AANGAAGTTCTCCAAAGGATAAAATCAGAACGAAACAAATTAAATCACATTCAAGTCGGATGACTACTTGTGGCTAA
K E V P P R I K S R T N Q I K I T F K S D D Y F V A K
561 ACCTGGATTCAAGATTATTCTTGTGGAAAGATTTCACCCGGAGCTTCAGAGAACAACTGGAAATCTGTCA
P G F K I Y Y S L L E D F Q P A A A S E T N W E S V T
641 CAAGCTTATTCAGGGGTATCTATAATCTCCATCAAGGATCCCACACTGATTGCGGATGCTCTGGACAAAAAA
S S I S G V S Y N S P S V T D P T L I A D A L D K K
721 ATTGCGAGAATTGATACAGTGGAAAGATCTGTCAGTACTTCATGGCAAGAACAGATTTGAGAATATGTA
I A E F D T V E D L L K Y F N P E S W Q E D L E N M Y
801 TCTGGACACCCCTCGGTATGGGAGGTATACCATGACGGAAACTGGCTGACCTGGATAGGCTCAATGATGATG
L D T P R Y R G R S Y H D R K S K V D L D R L N D D A
881 CCAAGGTTACAGTTGCACTCCAGGAATTACTGGTCAATATAAGAGAACAGCTGAAAGTTGGCCAATGTTGCTT
K R Y S C T P R N Y S V N I R E E L K L A N V V F F
961 CCACGTTGCTCTGCTGCGAGGAAATTGTGGCTGCGAACCTGCAACTGGAGGTCTGCAACATGCAATT
P R C L L V Q R C G G N C G C G T V N W R S C T C N S
1041 AGGGAAACCGTGAAGGATATCATGAGCTTACAGTTGGAGCTGGCACATCAAGAGGGTAGAGCTAACAGCCA
G K T V K K Y H E V L Q F E P G H I K R R G R A K T M
1121 TGGCTCTAGTTGACATCCAGTTGGATCACCATGAAACGATGTGATTGATCTGCAAGAACACCTGGATTAAGAGAA
A L V D I Q L D H H E R C D C I C S S R P P R (SEQ ID NO:20)
1201 GTGCACATCTTACATTAAGGCTGAAAGAACCTTGTGTTAAGGGGGGTGAGATAAGAGAACCTTTCTTACCCAGCAACC
1281 AAACTTACTACTAGCCTGCAATGCAATGAAACACAAAGTGGTGTGAGCTCAGCCTTGCTTGTAAATGCGATGGCAAGT
1361 AGAAAGGTATATCATCAACTCTATAACCTAAGAATATAGGATTGCAATTAAATAATAGTGTGTTGAGGTTATATATGCAACAA
1441 ACACACACAGAAATATTCATGTCATGTGTATATAGATCAAATGTTTTGGTATATATAACCAAGGTACACCAAGAG
1521 CTTACATATGTTGAGTTAGACTCTTAAATGCGAAAGGATGGTCAAATATATGAAACATGCTTTAGAA
1601 AATTAGGAGATAAAATTATTTAAATTGAAACACAAATTTGAATCTGCTCTTAAAGAAAAGCATCTTGT
1681 ATATTAAGGATGAGGCTTCTTACATATACATCTTAGTGT (SEQ ID NO:21)

FIG. 14




FIG. 15

| | | V5 6HIS |
|-----------|---|---|
| A. 27 KDa |  | GRSYHDRSKVLDRL (SEQ ID NO:22) |
| |  | GRSYHDRSKVD..... (SEQ ID NO:23) |
| B. 16 KDa |  | GRSYHDRSKVLDRL (SEQ ID NO:24) |
| |  | GRSYHDRSKVD..... (SEQ ID NO:25) |
| C. 6 KDa |  | V5 6HIS |
| |  | RGRAKTMALVDIQLDHHE (SEQ ID NO:26) |
| |  | RGRAKTMALVDIQ..... (SEQ ID NO:27) |

FIG. 16




FIG. 17




FIG. 18

Competition of 30664188 p30 or PDGF BB by 30664188 p85




FIG. 19




FIG. 20

CCD1070 Growth: Competition by Anti-Receptor Antibodies




FIG. 21

Smooth Muscle Treated with p30 30664188, PDGF AA, PDGF BB




FIG. 22




FIG. 23




FIG. 24

Neutralization of 30664188 by Fully Human Polyclonal Ab




Fig. 25.

Panel A




Fig. 25 (cont.)

Panel B




FIG. 26.

BrdU CCD1070 Soluble Alpha PDGFR Competition




FIG. 27A




FIG. 27B




FIG. 28

32D Alpha PDGFR Proliferation




FIG. 29A




FIG. 29B




FIG. 29C




FIG. 29D

